Dmitriy Zamarin, Ph.D.

2006 Icahn School of Medicine at Mount Sinai, New York, NY, United States 
Microbiology Biology, Pharmacology, Immunology
"Dmitriy Zamarin"


Sign in to add mentor
Peter Palese grad student 2006 Mount Sinai School of Medicine
 (Functional and pathogenic properties of the influenza virus PB1 -F2 protein and development of live attenuated influenza virus vaccines.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Khushalani NI, Harrington KJ, Melcher A, et al. (2023) Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment. Molecular Therapy Oncolytics. 31: 100729
Burman B, Pesci G, Zamarin D. (2020) Newcastle Disease Virus at the Forefront of Cancer Immunotherapy. Cancers. 12
Campesato LF, Budhu S, Tchaicha J, et al. (2020) Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nature Communications. 11: 4011
Raghavan S, Snyder CS, Wang A, et al. (2020) Carcinoma-Associated Mesenchymal Stem Cells Promote Chemoresistance in Ovarian Cancer Stem Cells via PDGF Signaling. Cancers. 12
Zamarin D, Hamid O, Nayak-Kapoor A, et al. (2020) Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: a Phase I Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Boland JL, Zhou Q, Iasonos AE, et al. (2020) Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy. Gynecologic Oncology
Zamarin D, Walderich S, Holland A, et al. (2020) Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. Journal For Immunotherapy of Cancer. 8
Jiménez-Sánchez A, Cybulska P, Mager KL, et al. (2020) Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nature Genetics
Nguyen B, Mota JM, Nandakumar S, et al. (2020) Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. European Urology
Zamarin D, Burger RA, Sill MW, et al. (2020) Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902059
See more...